In a retrospective study, clinical, histopathological and immunohistochemical findings of basaloid squamous cell carcinoma (BSCC) of the hypopharynx are analyzed and compared with the literature. Among 196 patients treated for hypopharyngeal carcinoma between January 1993 and December 2000, 6 patients fulfilled the morphological and immunohistochemical criteria of a BSCC. Three primary tumors were initially classified as T3 and 3 as T1, 3 presented with lymph node metastases. In no case was the BSCC associated with another primary neoplasm. Two patients developed distant metastases during the follow-up and died from the disease at 26 and 35 months. Four patients are alive with no evidence of disease at 27, 29, 61 and 87 months. We observed a contrast in the clinical behavior between the cases reported in the literature and our cases, as our BSCC of the hypopharynx were not detected at a more advanced stage than were the SCC and were in no case associated with another second primary tumor. However, the number of our cases is too small to draw reliable conclusions.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.